William O. S. Salvador
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
William O. S. Salvador has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Carlos André Vitorino Rodrigues
Department of Bioengineering, IBB—Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
2 shared publications - Diogo E. S. Nogueira
Department of Bioengineering and IBB – Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
1 shared publication Diogo E.S. Nogueira
1 shared publicationFrederico Castelo Ferreira
1 shared publication- Frederico Castelo Ferreira
Department of Bioengineering and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal
1 shared publication - Inês A. B. Ribeiro
Department of Bioengineering, IBB—Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
1 shared publication
Latest Publications
- Open Access
- 22 November 2023
- Published by Elsevier in Current Research in Biotechnology
- Vol. 6
BEMSCA: A novel decision support tool applied to the optimal design of a large-scale human induced pluripotent stem cell expansion bioprocess
- 22 November 2023
- Published by Elsevier in Current Research in Biotechnology
- Vol. 6
Open AccessBEMSCA: A novel decision support tool applied to the optimal design of a large-scale human induced pluripotent stem cell expansion bioprocess
- Open Access
- 11 December 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (12) , 791
Bioprocess Economic Modeling: Decision Support Tools for the Development of Stem Cell Therapy Products
Over recent years, the field of cell and gene therapy has witnessed rapid growth due to the demonstrated benefits of using living cells as therapeutic agents in a broad range of clinical studies and trials. Bioprocess economic models (BEMs) are fundamental tools for guiding decision-making in bioprocess design, being capable of supporting process optimization and helping to reduce production costs. These tools are particularly important when it comes to guiding manufacturing decisions and increasing the likelihood of market acceptance of cell-based therapies, which are often cost-prohibitive because of high resource and quality control costs. Not only this, but the inherent biological variability of their underlying bioprocesses makes them particularly susceptible to unforeseen costs arising from failed or delayed production batches. The present work reviews important concepts concerning the development of bioprocesses for stem cell therapy products and highlights the valuable role which BEMs can play in this endeavor. Additionally, some theoretical concepts relevant to the building and structuring of BEMs are explored. Finally, a comprehensive review of the existent BEMs so far reported in the scientific literature for stem cell-related bioprocesses is provided to showcase their potential usefulness.
- 11 December 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (12) , 791
Open AccessBioprocess Economic Modeling: Decision Support Tools for the Development of Stem Cell Therapy Products
Over recent years, the field of cell and gene therapy has witnessed rapid growth due to the demonstrated benefits of using living cells as therapeutic agents in a broad range of clinical studies and trials. Bioprocess economic models (BEMs) are fundamental tools for guiding decision-making in bioprocess design, being capable of supporting process optimization and helping to reduce production costs. These tools are particularly important when it comes to guiding manufacturing decisions and increasing the likelihood of market acceptance of cell-based therapies, which are often cost-prohibitive because of high resource and quality control costs. Not only this, but the inherent biological variability of their underlying bioprocesses makes them particularly susceptible to unforeseen costs arising from failed or delayed production batches. The present work reviews important concepts concerning the development of bioprocesses for stem cell therapy products and highlights the valuable role which BEMs can play in this endeavor. Additionally, some theoretical concepts relevant to the building and structuring of BEMs are explored. Finally, a comprehensive review of the existent BEMs so far reported in the scientific literature for stem cell-related bioprocesses is provided to showcase their potential usefulness.